Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?
Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?